The role of structured inpatient lipid protocols in optimizing non-statin lipid lowering therapy: a review and single-center experience

被引：1

作者：

Gier, Chad ^{[1
]}

Gilchrist, Ian ^{[1
]}

Fordham, Matthew ^{[1
]}

Riordan, Luke ^{[1
]}

Milchan, Ella ^{[2
]}

Patel, Nidhi ^{[2
]}

Mohedi, Azad ^{[2
]}

Choudhury, Sahana ^{[1
]}

Kits, Tara ^{[1
]}

Cohen, Regina ^{[1
]}

Doughtery, Joseph ^{[1
]}

Reilly, John P. ^{[1
]}

Kalogeropoulos, Andreas ^{[1
]}

Rahman, Tahmid ^{[1
]}

Chen, On ^{[1
]}

机构：

[1] Stony Brook Univ Hosp, Stony Brook Heart Inst, Stony Brook, NY 11794 USA

[2] Stony Brook Renaissance Sch Med, Stony Brook, NY USA

来源：

FRONTIERS IN CARDIOVASCULAR MEDICINE | 2024年 / 11卷

关键词：

hyperlipidemia; quality improvement; ASCVD; lipid lower medications; LDL-Cholesterol; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; BEMPEDOIC ACID; EFFICACY; SAFETY;

D O I：

10.3389/fcvm.2024.1284562

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dyslipidemia is a leading contributor to atherosclerotic cardiovascular disease (ASCVD). There has been a significant improvement in the treatment of dyslipidemia in the past 10 years with the development of new pharmacotherapies. The intent of this review is help enhance clinicians understanding of non-statin lipid lowering therapies in accordance with the 2022 American College of Cardiology Expert Consensus Clinical Decision Pathway on the Role of Non-statin Therapies for LDL-Cholesterol Lowering. We also present a single-center experience implementing a systematic inpatient protocol for lipid lowering therapy for secondary prevention of ASCVD.

引用

页数：6